Peter Buhl Jensen
St. Jude Children's Research Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Buhl Jensen.
Journal of Biological Chemistry | 2000
Lars H. Jensen; Karin C. Nitiss; Angela Rose; Jiaowang Dong; Junfang Zhou; Tao Hu; Neil Osheroff; Peter Buhl Jensen; Maxwell Sehested; John L. Nitiss
Bisdioxopiperazines are a unique class of topoisomerase II inhibitors that lock topoisomerase II at a point in the enzyme reaction cycle where the enzyme forms a closed clamp around DNA. We examined cell killing by ICRF-187 and ICRF-193 in yeast cells expressing human topoisomerase II α (htop-IIα). Expression of htop-IIα in yeast cells sensitizes them to both ICRF-187 and ICRF-193, compared with cells expressing yeast topoisomerase II. ICRF-193 is still able to exert growth inhibition in the presence of genes encoding both ICRF-193-resistant and ICRF-193-sensitive htop-IIα enzymes, indicating that sensitivity to bisdioxopiperazines is dominant. Killing by ICRF-193 occurs more rapidly, than the killing in yeast cells due to a temperature-sensitive yeast topoisomerase II incubated at the non-permissive temperature. These results are reminiscent of a top-II poison such as etoposide. However, the killing caused by ICRF-193 and ICRF-187 is not enhanced by mutations in theRAD52 pathway. The levels of drug-induced DNA cleavage observed with htop-IIα in vitro is insufficient to explain the sensitivity induced by this enzyme in yeast cells. Finally, arrest of cells in G1 does not protect cells from ICRF-193 lethality, a result inconsistent with killing mechanisms due to catalytic inhibition of top-II or stabilization of a cleavable complex. We suggest that the observed pattern of cell killing is most consistent with a poisoning of htop-II by ICRF-193 by a novel mechanism. The accumulation of closed clamp conformations of htop-II induced by ICRF-193 that are trapped on DNA might interfere with transcription, or other DNA metabolic processes, resulting in cell death.
Journal of Biological Chemistry | 2004
Jerrylaine Walker; Karin C. Nitiss; Lars H. Jensen; Christopher Mayne; Tao Hu; Peter Buhl Jensen; Maxwell Sehested; Tao Hsieh; John L. Nitiss
Type II DNA topoisomerases are ATP-dependent enzymes that catalyze alterations in DNA topology. These enzymes are important targets of a variety of anti-bacterial and anti-cancer agents. We identified a mutation in human topoisomerase II α, changing aspartic acid 48 to asparagine, that has the unique property of failing to transform yeast cells deficient in recombinational repair. In repair-proficient yeast strains, the Asp-48 → Asn mutant can be expressed and complements a temperature-sensitive top2 mutation. Purified Asp-48 → Asn Top2α has relaxation and decatenation activity similar to the wild type enzyme, but the purified protein exhibits several biochemical alterations compared with the wild type enzyme. The mutant enzyme binds both covalently closed and linear DNA with greater avidity than the wild type enzyme. hTop2α(Asp-48 → Asn) also exhibited elevated levels of drug-independent cleavage compared with the wild type enzyme. The enzyme did not show altered sensitivity to bisdioxopiperazines nor did it form stable closed clamps in the absence of ATP, although the enzyme did form elevated levels of closed clamps in the presence of a non-hydrolyzable ATP analog compared with the wild type enzyme. We suggest that the lethality exhibited by the mutant is likely because of its enhanced drug-independent cleavage, and we propose that alterations in the ATP binding domain of the enzyme are capable of altering the interactions of the enzyme with DNA. This mutant enzyme also serves as a new model for understanding the action of drugs targeting topoisomerase II.
Archive | 2002
Peter Buhl Jensen; Birgitte Søkilde; Elisabeth V. Carstensen; Seppo W. Langer; Andrew M. Creighton; Maxvell Sehested; Lars H. Jensen
Archive | 2009
Maxwell Sehested; Peter Buhl Jensen; Nis I. Nissen
Archive | 1997
Peter Buhl Jensen; Maxwell Sehested
Archive | 2000
Seppo W. Langer; Peter Buhl Jensen; Maxwell Sehested
Archive | 2005
Kenneth Francis Hofland; Maxwell Sehested; Paul E.G. Kristjansen; Annemette V. Thougaard; Peter Buhl Jensen
Archive | 2005
Kenneth Francis Hofland; Maxwell Sehested; Paul E.G. Kristjansen; Annemette V. Thougaard; Peter Buhl Jensen
Archive | 2000
Peter Buhl Jensen; Seppo W. Langer; Maxwell Sehested
Archive | 2000
Peter Buhl Jensen; Seppo W. Langer; Maxwell Sehested